These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34169667)

  • 21. Pseudoprogression after glioma therapy: an update.
    Galldiks N; Kocher M; Langen KJ
    Expert Rev Neurother; 2017 Nov; 17(11):1109-1115. PubMed ID: 28862482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
    Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
    Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deep learning in the detection of high-grade glioma recurrence using multiple MRI sequences: A pilot study.
    Bacchi S; Zerner T; Dongas J; Asahina AT; Abou-Hamden A; Otto S; Oakden-Rayner L; Patel S
    J Clin Neurosci; 2019 Dec; 70():11-13. PubMed ID: 31648967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
    Dhermain F
    Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiating between Central Nervous System Lymphoma and High-grade Glioma Using Dynamic Susceptibility Contrast and Dynamic Contrast-enhanced MR Imaging with Histogram Analysis.
    Murayama K; Nishiyama Y; Hirose Y; Abe M; Ohyu S; Ninomiya A; Fukuba T; Katada K; Toyama H
    Magn Reson Med Sci; 2018 Jan; 17(1):42-49. PubMed ID: 28515410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis.
    Liang J; Liu D; Gao P; Zhang D; Chen H; Shi C; Luo L
    Acad Radiol; 2018 Mar; 25(3):338-348. PubMed ID: 29223713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
    Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
    BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiotherapy target volume definition in newly diagnosed high grade glioma using
    Dissaux G; Dissaux B; Kabbaj OE; Gujral DM; Pradier O; Salaün PY; Seizeur R; Bourhis D; Ben Salem D; Querellou S; Schick U
    Radiother Oncol; 2020 Sep; 150():164-171. PubMed ID: 32580001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach.
    Latysheva A; Emblem KE; Brandal P; Vik-Mo EO; Pahnke J; Røysland K; Hald JK; Server A
    Neuroradiology; 2019 May; 61(5):545-555. PubMed ID: 30712139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Dynamic Susceptibility Contrast Perfusion MRI in Glioma Progression Evaluation.
    Quan G; Zhang K; Liu Y; Ren JL; Huang D; Wang W; Yuan T
    J Oncol; 2021; 2021():1696387. PubMed ID: 33628239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
    Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
    J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Utility of Diffusion and Perfusion Magnetic Resonance Imaging in Target Delineation of High-Grade Gliomas.
    Fei Q; Qian LX; Zhang YJ; Guo WJ; Bian XH; Yin L; Yan PW; Wang TT; Qian PD; Guo Z; He X
    Biomed Res Int; 2020; 2020():8718097. PubMed ID: 32851090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic susceptibility contrast and dynamic contrast-enhanced MRI characteristics to distinguish microcystic meningiomas from traditional Grade I meningiomas and high-grade gliomas.
    Hussain NS; Moisi MD; Keogh B; McCullough BJ; Rostad S; Newell D; Gwinn R; Foltz G; Mayberg M; Aguedan B; Good V; Fouke SJ
    J Neurosurg; 2017 Apr; 126(4):1220-1226. PubMed ID: 27285539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI.
    Lin Y; Xing Z; She D; Yang X; Zheng Y; Xiao Z; Wang X; Cao D
    Neuroradiology; 2017 Jun; 59(6):555-562. PubMed ID: 28474187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined value of susceptibility-weighted and perfusion-weighted imaging in assessing who grade for brain astrocytomas.
    Wang XC; Zhang H; Tan Y; Qin JB; Wu XF; Wang L; Zhang L
    J Magn Reson Imaging; 2014 Jun; 39(6):1569-74. PubMed ID: 24987755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery.
    Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y
    Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
    Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
    J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma: diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters.
    Aslan K; Gunbey HP; Tomak L; Incesu L
    Neurol Neurochir Pol; 2019; 53(3):227-237. PubMed ID: 31180131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.